Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KIORA PHARMACEUTICALS INCEYEG · Entity 7940 | Director | February 01, 2021 | February 04, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KIORA PHARMACEUTICALS INC
Report date February 01, 2021 · Filed February 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.46 · Expires 2031-02-01 | Direct | 3,333 |
Reported balance
After 2021-02-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-01 · Grant · Acquired 3,333 · Balance 3,333 F1: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on February 1, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on February 1, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2021 Filed Feb 4, 2021 02:51 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | GrantStock Option (right to buy) · Derivative | 3,333 | $0.00 Strike: $6.46 | $0.00 |
DisclosureSEC source: 0001104659-21-011845 · tm215262-3_4seq1.xml · derivative · entry 1 GOLDBERG MORTON · CIK 0001619731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Underlying: Common Stock · 3,333 shares Expires 2031-02-01 F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on February 1, 2022. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:31 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | GrantStock Option (right to buy) · Derivative | 3,333 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001104659-20-022844 · tm209305-4_4.xml · derivative · entry 1 GOLDBERG MORTON · CIK 0001619731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Underlying: Common Stock · 3,333 shares Expires 2030-02-14 F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Plan. The Option will become fully exercisable on February 1, 2021. Read SEC document |
| December 06, 2019 Filed Dec 6, 2019 23:45 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | SaleCommon Stock | 1,961 | $6.93 | $13,589.73 |
DisclosureSEC source: 0001104659-19-070723 · tm1924718-1_4.xml · nonDerivative · entry 1 GOLDBERG MORTON · CIK 0001619731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| November 12, 2019 Filed Nov 13, 2019 21:18 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | SaleCommon Stock | 2,001 | $4.29 | $8,584.29 |
DisclosureSEC source: 0001104659-19-063335 · tm1922769-1_4.xml · nonDerivative · entry 1 GOLDBERG MORTON · CIK 0001619731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,961 F1 · balance_after: Effective as of 08/30/2019, the Issuer effected a 1-for-15 reverse split of its common stock. The number of shares reflects the reverse stock split. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 21:38 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001144204-19-005049 · tv512447_form4.xml · derivative · entry 1 GOLDBERG MORTON · CIK 0001619731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-02-01 F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to 100% of the shares underlying the Option on February 1, 2020. Read SEC document |
| July 10, 2018 Filed Jul 12, 2018 20:57 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-038187 · tv498478_4.xml · nonDerivative · entry 1 GOLDBERG MORTON · CIK 0001619731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,441 F1 · shares: Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The restrictions will vest as to all of the shares on July 10, 2019. Read SEC document |
| June 21, 2017 Filed Jun 22, 2017 20:17 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001144204-17-033618 · v469450_4.xml · derivative · entry 1 GOLDBERG MORTON · CIK 0001619731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-21 F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to 100% of the shares underlying the Option on June 21, 2018. Read SEC document |
| March 06, 2017 Filed Mar 6, 2017 21:05 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | SaleCommon Stock | 8,919 | $3.00 | $26,757.00 |
DisclosureSEC source: 0001144204-17-012941 · v461231_4.xml · nonDerivative · entry 1 GOLDBERG MORTON · CIK 0001619731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,441 Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 22:24 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | Exercise / conversionStock Option (right to buy) · Derivative | 1,083 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001144204-17-012195 · v460895_4.xml · derivative · entry 2 GOLDBERG MORTON · CIK 0001619731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,917 Underlying: Common Stock · 1,083 shares Expires 2026-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The reporting person was granted an option to purchase these shares pursuant to the Issuer's 2014 Equity Incentive Plan. The option became exercisable as to 33% of the shares underlying the option on January 25, 2017, with 2.78% of the shares underlying the option vesting monthly thereafter. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 22:24 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | Exercise / conversionCommon Stock | 1,083 | $1.70 | $1,841.10 |
DisclosureSEC source: 0001144204-17-012195 · v460895_4.xml · nonDerivative · entry 1 GOLDBERG MORTON · CIK 0001619731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,360 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.